For Lorraine Simpson, a Chicago-based sales representative with Professional Detailing Inc., there are no downsides to working for a contract sales organization. "I'm telling you, it's wonderful!" she said. "But the perception is that in contractual work, you don't work as hard and you're not on the same level. In my opinion, we work just as hard."
For Lorraine Simpson, a Chicago-based sales representative with Professional Detailing Inc., there are no downsides to working for a contract sales organization. "I'm telling you, it's wonderful!" she said. "But the perception is that in contractual work, you don't work as hard and you're not on the same level. In my opinion, we work just as hard."
Challenge is built into the contract situation itself. "We want to see the contracts get renewed," Simpson explained. "So it's to our advantage to really work hard to prove to the company that we can increase sales."
"The expectations are just the same - you see a certain number of physicians, do sales promotions ... your managers and evaluations are the same. The only difference is that you usually don't have the entertainment budgets that other companies have," she said. "So therefore, your evening and weekend programs are less."
Simpson got her start as a full-time, "noncontract" sales representative with Syntex Laboratories in the early 1980s. After taking a break from her sales career and having a son, Simpson came back to work - this time as a contract rep. With an active family life, social and community calendar, art and gardening, the less hectic evening schedule is a plus.
"What I like is the diversity of all of it - learning a new product, meeting different people," Simpson said. And her company has helped. "I have probably done more interesting things with PDI than I've ever been able to do before." As for the old, "noncontract" days? Simpson said, "I haven't looked back since!"
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.